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Abstract
Background: Little is known about preoperative predictors of resource utilization in the treatment of high-risk
patients with severe symptomatic aortic valve stenosis. We report results from the prospective, medical-economic
“TAVI Calculation of Costs Trial”.
Methods: In-hospital resource utilization was evaluated in 110 elderly patients (age ≥ 75 years) treated either with
transfemoral (TF) or transapical (TA) transcatheter aortic valve implantation (TAVI, N = 83), or surgical aortic valve
replacement (AVR, N = 27). Overall, 22 patient-specific baseline parameters were tested for within-group prediction
of resource use.
Results: Baseline characteristics differed between groups and reflected the non-randomized, real-world allocation
of treatment options. Overall procedural times were shortest for TAVI, intensive care unit (ICU) length of stay (LoS)
was lowest for AVR. Length of total hospitalization since procedure (THsP) was lowest for TF-TAVI; 13.4 ± 11.4 days
as compared to 15.7 ± 10.5 and 21.2 ± 15.4 days for AVR and TA-TAVI, respectively. For TAVI and AVR, EuroScore I
remained the main predictor for prolonged THsP (p <0.01). Within the TAVI group, multivariate regression analyses
showed that TA-TAVI was associated with a substantial increase in THsP (55 to 61 %, p <0.01). Additionally, preoperative
aortic valve area (AVA) was identified as an independent predictor of prolonged THsP in TAVI patients, irrespective of
risk scores (p <0.05).
Conclusions: Our results demonstrate significant heterogeneity in patients baseline characteristics dependent
on treatment and corresponding differences in resource utilization. Prolonged ThsP is not only predicted by risk
scores but also by baseline AVA, which might be useful in stratifying TAVI patients.
Trial registration: German Clinical Trial Register Nr. DRKS00000797
Keywords: Transcatheter aortic valve implantation, Aortic valve replacement, Resource utilization, Risk prediction,
Cost, Length of stay, Total hospitalization since procedure
Background
Due to the steadily increasing life expectancy in Western
countries such as Germany, the prevalence of patients
presenting with degenerative calcific aortic valve stenosis
(AS) is rapidly increasing. As a result, both the clinical
and economic aspects of their treatment are of high
interest. The German Aortic Valve Registry (GARY) was
initiated as a starting point for the investigation of these
issues, and its first published findings confirm the desir-
ability of better data on this subject [1–3].
Since the commercial launch of transcatheter aortic
valve implantation (TAVI) in 2007, the technique has
been widely adopted by cardiologists and cardiac sur-
geons, with more than 100,000 procedures performed
worldwide by the end of 2013 [4, 5]. The results ofthe
PARTNER trial have shown outstanding benefits over a
period of 3 years in inoperable and high risk patients
with severe AS [6–9]. However, for the technically op-
erable high risk population surgical aortic valve re-
placement (AVR) continues to be regarded as the gold
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standard treatment due to the long-standing clinical
experience with the technique. Despite this there is an
ongoing debate, notably in the light of the recently up-
dated guidelines on the management of valve disease
from the ESC & EACTS, as to where these two thera-
peutic alternatives should be positioned from both the
clinical, and, inevitably, economic perspectives [10].
A better resource utilization is becoming a “real” prob-
lem in the medical field. A correct evaluation of the costs
has to be done for every new procedure.
Due to the technique’s relatively recent introduction
into clinical practice, several analyses measuring the in-
hospital costs and cost-effectiveness of TAVI have been
published in the last two years, and these have been
reviewed recently [11–15]. They all present their re-
sults for either inoperable (deemed unsafe for surgery)
or high-risk patients (where surgery is not ruled out,
but not without substantial risk), and overall TAVI is
shown as cost-effective versus medical therapy/conse-
rvative treatment, however for TAVI versus surgical
AVR the results are mixed. Although these studies aimed
to make a comparison of the economic aspects of the
treatments, they do not directly compare detailed re-
source usage.
This study sought to define and evaluate preoperative
risk factors suitable for the prediction of comparative
resource utilization in the treatment of symptomatic
AS in elderly patients based on a real world patient co-




The TAVI calculation of costs trial (TCCT) was designed
as a prospective observational multicenter cohort study
on elderly patients with symptomatic AS receiving either
AVR or TAVI. This study was approved by the institu-
tional ethics committee (Research Ethics Committee
Albert-Ludwigs-Universität Freiburg, Germany, ID:
52/11), and was registred in the German Clinical Trial
Register (ID: DRKS00000797). All patients referred
between April 2011 and March 2013 to our centers
were considered for inclusion into the study. Age
above 75 years was deliberately chosen as inclusion
criteria with the intention to avoid overwhelming the
AVR treatment arm with data on substantially lower
risk patients. All treatment decisions were made by a
study-independent “heart team” of cardiac surgeons
and cardiologists according to best clinical practice. A
total of 10 AVR patients that underwent additional
coronary artery bypass grafting were excluded from
the dataset due to the existence of an additional
procedure.
Resource utilization
A primary focus of the study was the use of healthcare
resources in treatment. To this end, we examined the
complete duration of hospital length of stay (LoS) from
admission until final discharge home or to a rehabili-
tation facility. We approached this by distinguishing two
components: 1) procedure-to-discharge LoS; the time
from procedure to discharge from the treating centre,
generally corresponding to hospital LoS in the literature,
and 2) post-discharge LoS; the time from initial treating
hospital discharge to final discharge from any other sub-
ordinate hospital. From these parameters, we further de-
rived a highly useful overall measure of LoS, the “total
hospitalisation since procedure” (THsP); combining
procedure-to-discharge LoS and post-discharge LoS.
For death prior to discharge, LoS was defined as the
time from procedure until the day of death. In addition,
all further relevant resource utilization characterized by
specific procedural parameters, e.g. duration on ventilator,
was also recorded and analyzed.
Statistical analysis
Quantitative continuous variables are described with
means ± standard deviations, and quantitative discrete
variables with absolute and relative frequencies. Differ-
ences between treatment groups were analysed using the
non-parametric Wilcoxon rank-sum test or Fisher’s exact
test. In order to identify suitable within group predictors
for in-hospital resource utilization, all baseline parameters
were tested against THsP, intensive care unit (ICU) LoS,
and time on ventilator. Complete information about re-
source use can only be retrieved for individuals who are
alive at follow-up, but a simple exclusion of individuals
with missing information can lead to serious bias in risk
prediction. Accordingly, patients who died during hospital
stay were censored using right-censored normal regression
analyses. In addition, the positive skew of the resource use
variables wasaccounted for by application of the natural
logarithm of all dependent variables (ln(x + 1)) in the few
cases where time on ventilator or ICU LoS were equal to
zero). Accordingly, the results may be interpreted as the
relative increase of the outcome (percentage changes in the
‘Length of hospital stay’, the ‘Length of mechanical venti-
lation’ or the ‘Length of ICU stay’) when comparing the
two levels of a binary covariate or a change by 1 unit of a
continuous covariate. Mean conditional imputation was
applied for missing variables. All analyses were performed
using Stata 12 (StataCorp, College Station, TX, USA).
Results
Patient population
The total study population comprised 110 patients
undergoing TF-TAVI (n = 60), TA-TAVI (n = 23), and
AVR (n = 27).
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Baseline demographics and characteristics are pro-
vided in Table 1. As treatment decisions were based on
clinical judgement according to patient presentation
and the decisions of a “heart team”, there were sub-
stantial differences between groups. AVR patients were
significantly younger (p <0.01) and exhibited signifi-
cantly lower EuroScore I (p <0.01), Euroscore II values
(p <0.01) and STS-Scores (p <0.01) than the TAVI pa-
tients. Among TAVI patients, patients with a TA ap-
proach were, on average, at higher risk than TF-TAVI,
although the differences in EuroScore I, EuroScore II
and STS score values were not statistically significant
(p = 0.065, p = 0.094, p = 0.505, respectively).
There also was a gender imbalance, with a higher propor-
tion of females undergoing TAVI (p = 0.029). This may,
however, be explained by the fact that women exhibited sig-
nificantly higher EuroScore I values (18.62 in comparison
to 15.56, p = 0.019). In addition, proBNP (B-type natiuretic
peptide) increased in line with EuroScore. Patients with
prior CABG were observed in 12 % of TAVI cases and 4 %
for AVR. Peripheral vascular disease (PVD) was most fre-
quent in the TA-TAVI groups, 30 % versus 4 % and 17 %
for AVR and TF-TAVI.
Resource utilization
AVR and TAVI procedural parameters (timings and staff)
and patient LoS are detailed in Table 2. Overall, time in
the cathlab or OR was shortest for TAVI and substantially
longer for AVR (p <0.01). Both TF and TA-TAVI averaged
around two hours (122 and 142 min, respectively),
whereas AVR averaged 218 min. Total time, defined as
the time a patient was anesthetised, was similarly di-
verse between TAVI and AVR patients (p <0.01). On
average, staff numbers required per procedure were:
3.5 physicians (including one trainee) and 2.7 nurses
for TAVI, and 2.7 physicians, 2.0 nurses, and a perfusionist
Table 1 Mean baseline characteristics of TAVI and AVR patients aged ≥ 75 years
AVR TAVI AVR vs. TAVI
All TF-TAVI TA-TAVI TF vs. TA-TAVI
27 83 60 23 p-value p-value
Demographics
Age 78.74 ±3.43 82.9 ±4.48 82.95 ±4.67 82.78 ±4.03 p <0.01 0.963
Female 44 % 67 % 68 % 65 % 0.029 0.798
Medical History
LVEF (%) 50.37 ±12.8 50.52 ±9.62 51.2 ±9.25 48.47 ±10.68 0.785 0.257
AVA 0.81 ±0.17 0.68 ±0.16 0.68 ±0.17 0.65 ±0.14 p <0.01 0.9796
Renal diseasea 56 % 64 % 57 % 83 % 0.183 0.043
CAD 37 % 54 % 55 % 52 % 0.183 1.000
Previous MI 11 % 22 % 17 % 35 % 0.272 0.084
Previous PCI 19 % 24 % 23 % 26 % 0.609 0.781
Previous Stroke 4 % 7 % 5 % 13 % 1.000 0.340
Previous CABG 4 % 12 % 8 % 22 % 0.288 0.131
AF 33 % 41 % 33 % 61 % 0.507 0.027
Hypertension 93 % 83 % 85 % 78 % 0.348 0.518
DM 33 % 27 % 25 % 30 % 0.623 0.782
Liver disease 4 % 6 % 5 % 9 % 1.000 0.614
COPD 11 % 16 % 13 % 22 % 0.757 0.336
PVD 4 % 20 % 17 % 30 % 0.068 0.224
Quality of lifeb 0.84 ±0.21 0.79 ±0.21 0.8 ±0.22 0.76 ±0.17 0.062 0.134
proBNP (pg/ml) 1474 ±1708 4098 ±6576 3820 ±6111 4805 ±7749 0.654 0.760
Risk Scores
EuroScore I 10.44 ±6.21 20.66 ±13.05 18.53 ±10.16 25.87 ±17.49 p <0.01 0.065
EuroScore II 3.54 ±3.15 6.77 ±5.59 5.83 ±4.09 9.04 ±7.84 p <0.01 0.094
STS-Score 3.48 ±1.57 5.7 ±3.36 5.48 ±2.88 6.21 ±4.35 p <0.01 0.505
Abbreviations: LVEF – left ventricular ejection fraction; AVA – preoperative aortic valve area; CAD – coronary artery disease; MI – myocardial infarction:
PCI – percutaneous coronary intervention; AF – atrial fibrillation; DM – diabetes mellitus; COPD – chronic obstructive pulmonary disease; PVD – peripheral
vascular disease; proBNP–B-type natiuretic peptide. Data are presented as n (%) or mean ± standard deviation
aRenal disease defined as (glomerular filtration rate <60 ml/h); bPatients quality of life at baseline according to standardized EQ-5D questionnaire
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for AVR. Notably, in our centres patients undergoing TAVI
are anesthetised in the OR before moving to the cathlab,
which substantially increases total time.
Time spent in the ICU varied greatly and was shortest
for AVR at 89 h (median 47.2 h). Interestingly, there was
very little difference in average ICU stay between TF-
and TA-TAVI at 105 h for both. The mean duration of
mechanical respiratory support was similar across the
groups, around 40 h (median range 8.6–12.8 h). Proced-
ure to discharge LoS was lowest for AVR (10.6 days) and
similar for TF-TAVI and TA-TAVI, with 13.1 and 13.0
days respectively. Notably, post-discharge LoS with TA-
TAVI and AVR was 8.2 and 5.1 days respectively, whereas
for TF-TAVI it was only 0.3 days. The large differences in
the mean post-discharge LoS between the different groups
is mostly explainable by the fact that TF-TAVI patients
were less often discharged to another hospital than TA-
TAVI and AVR patients. Average THsP by group, inclu-
ding time spent in subordinate hospitals, therefore was,
13.4 days for TF-TAVI, 15.7 days for AVR, and 21.2 days
for TA-TAVI. Accordingly, THsP was different between
TF and TA-TAVI patients (p <0.01), but relatively equal
between AVR and TAVI patients (p = 0.3058).
Predictors of in-hospital resource use following TAVI
According to univariate regression analyses (see Table 3),
significant predictors (p <0.05) for prolonged THsP were:
TA procedure, aortic valve area (AVA), history of atrial fib-
rillation (AF) and/or PVD, as well as higher EuroScore I,
EuroScore II and STS Score.
The standard risk scores already cover most of the pa-
rameters identified in our calculation as predictive for an
increased resource usage. However, neither AVA or AF
are included in the cacluation of these scores, and so we
hypothesised that they might represent additional variables
which could be used by the clinician to predict outcomes.
Accordingly, we fitted three multivariate regression models
in order to analyse whether the baseline parameters of AVA
and AF as well as the access route (TA) are predictors
of in-hospital resource use for TAVI, independent of
the predictive value of the three risk scores. As shown
in Table 4, the TA approach was still associated with a
Table 2 Procedural times, staff utilization, patient in-hospital length of stay and discharge behaviour of TAVI and AVR patients
aged ≥ 75 years
TF-TAVI (60) TA-TAVI (23) AVR (27)
Procedural resource utilization
Time cathlab/OR (min.) 122.3 ± 40.5 (118.5) 142.3 ± 96.9 (109) 217.7 ± 48.8 (223)
Staff
Physician 3.58 ± 0.59 (4) 3.17 ± 0.72 (3) 2.67 ± 0.62 (3)
Nurse 2.55 ± 0.59 (3) 2.91 ± 0.29 (3) 2.04 ± 0.19 (2)
Time anesthesia (min.) 238.3 ± 55.4 (245) 247.5 ± 80.4 (220) 327.9 ± 57.6 (325)
Staff
Physician 1.0 ± 0.0 (1) 1.96 ± 0.21 (2) 1.93 ± 0.27 (2)
Nurse 1.02 ± 0.34 (1) 0.32 ± 0.02 (0.33) 0.33 ± 0.15 (0.33)
Perfusionistsa 0 (0) 0 (0) 1.0 ± 0.0 (1)
Post-procedural resource utilization
Time spent in ICU (hours) 105.0 ± 198.6 (62.7) 105.4 ± 100.4 (66.1) 89.0 ± 131.0 (47.2)
Time on ventilation (hours) 35.8 ± 110.7 (8.6) 35.7 ± 64.6 (9.2) 42.6 ± 115.8 (12.8)
Length of stay (days)
Procedure to discharge 13.1 ± 11.3 (10) 13.0 ± 6.6 (10) 10.6 ± 4.6 (10)
Post-discharge LoS 0.3 ± 1.4 (0) 8.2 ± 13.6 (0) 5.1 ± 7.0 (4)
Total hospitalisation since procedure 13.4 ± 11.4 (10) 21.2 ± 15.4 (17) 15.7 ± 10.5 (14)
Discharge destination
Home 46.7 % 13 % 0 %
Rehabilitation 40 % 26.1 % 44.4 %
Hospital 5 % 43.5 % 51.9 %
Nursing Home 3.3 % 0 % 0 %
In-hospital death 5 % 17.4 % 3.7 %
Data are presented as mean ± standard deviation and median in parentheses
aIn our centers an extracorporeal life-support system and perfusionists are on stand-by for all TAVI procedures
Reinöhl et al. BMC Cardiovascular Disorders  (2015) 15:132 Page 4 of 9
substantial (approximately 55 to 61 %) increase in
THsP. Moreover, AVA appeared to be an independent
predictor of THsP irrespective of which risk-score we
adjusted for: Table 4, model (1) contains an adjustment
for the EuroScore I, model (2) for the EuroScore II and
model (3) for the STS-Score. If we focus on AVA as a
predictive factor additional to EuroScore I as shown in
model (1), our results indicate that for every reduction
in AVA of 0.1 cm2, the predicted THsP increases by
5.2 %, which is equivalent to almost one additional day
of hospitalization (see also Fig. 1).
Predictors of in-hospital resource use following AVR
Similarly, for AVR (see Table 5) a significant predictor in
univariate analysis (p <0.05) for prolonged THsP were
the STS-Scores. Moreover, a low value of the glomerular
Table 3 Univariate predictors of in-hospital resource use following TAVI (N = 83)
Length of THsP (in days) Length of mechanical ventilation (in hours) Length of ICU stay (in hours)
% change p-value % change p-value % change p-value
TA 69.05 %*** (0.000) 65.04 % (0.158) 4.97 % (0.820)
Age (per one-year change) 0.81 % (0.620) 4.57 % (0.216) 1.64 % (0.371)
Female 6.16 % (0.669) −25.17 % (0.440) −4.81 % (0.813)
Quality of life −1.06 % (0.686) −0.34 % (0.959) −1.62 % (0.589)
LVEF (per one-unit increase) −1.72 % (0.085) −4.60 %* (0.041) −2.18 % (0.139)
AVA (for increase of 0.1 cm2) −5.62 %* (0.018) −8.08 %* (0.042) −5.40 % (0.069)
GFR (per one-unit change) −0.58 % (0.060) −1.26 % (0.062) −0.77 %* (0.031)
CAD 20.20 % (0.158) 52.20 % (0.194) 19.72 % (0.290)
Previous MI 5.50 % (0.762) 24.23 % (0.580) −1.34 % (0.952)
Previous PCI 17.94 % (0.305) −9.61 % (0.792) 1.21 % (0.957)
Previous Stroke 46.67 % (0.304) 29.30 % (0.390) 31.00 % (0.451)
Previous CABG 10.74 % (0.546) −15.38 % (0.730) −10.60 % (0.673)
AF 34.31 %* (0.042) 54.96 % (0.205) 33.51 % (0.130)
Hypertension −24.87 % (0.152) −60.90 %* (0.048) −39.47 %* (0.016)
DM 7.14 % (0.668) 11.18 % (0.797) −0.63 % (0.979)
Liver disease 33.78 % (0.364) −6.11 % (0.953) 5.24 % (0.908)
COPD −2.25 % (0.876) 116.19 % (0.184) 49.18 % (0.128)
PVD 46.37 %* (0.021) 44.63 % (0.441) 33.91 % (0.282)
EuroScore I (per one-unit change) 1.37 %* (0.010) 4.76 %*** (0.000) 1.89 %* (0.014)
EuroScore II (per one-unit change) 2.76 %* (0.039) 6.82 % (0.064) 3.05 % (0.158)
STS Score (per one-unit change) 3.71 %* (0.032) 10.05 % (0.109) 6.27 % (0.068)
proBNP (per 100 pg/ml change) 0.03 % (0.709) 0.14 % (0.675) 0.20 % (0.253)
p-values in parentheses; *p <0.05, **p <0.01, ***p <0.001
Table 4 Multivariate predictors of Length of hospital stay following TAVI (N = 83)
Length of hospital stay (THsP)
model 1 model 2 model 3
% change p-value % change p-value % change p-value
TA 54.65 %** (0.003) 55.89 %** (0.003) 61.45 %** (0.001)
AVA (per change of 0.1 cm2) −5.20 %* (0.025) −5.50 %* (0.015) −5.28 %* (0.022)
AF 21.17 % (0.171) 20.20 % (0.197) 18.65 % (0.241)
EuroScore I (per one-unit change) 0.83 % (0.067)
EuroScore II (per one-unit change) 1.42 % (0.210)
STS Score (per one-unit change) 1.83 % (0.220)
N 83 83 83
p-values in parentheses; *p <0.05, **p <0.01, ***p <0.001
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filtration rate at baseline was a predictor for prolonged
time on ventilation, whereas patients with a medical his-
tory of diabetes spent less time in ICU settings.
Discussion
Our investigation showed that resource utilization differs
substantially and significantly between therapy options for
severe AS in the elderly, with TF patients experiencing
shorter overall LoS (THsP) compared to other options.
We hypothesise that the early diagnosis and treatment of
symptomatic patients is optimal for reducing healthcare
resource utilization and have shown that AVA, as a surr-
ogate for the progress of the disease, is an independent
predictor of this. As it is not considered in the three
Fig. 1 Multivariate predictors of Length of hospital stay following TAVI (N = 83). Point estimates and confidence intervals of the changes in
length of hospital stay (see model (1) in Table 4)
Table 5 Univariate predictors of in-hospital resource use following AVR (N = 27)
Length of THsP (in days) Length of mechanical ventilation (in hours) Length of ICU stay (in hours)
% change p-value % change p-value % change p-value
Age (per one-year change) 0.55 % (0.757) 1.63 % (0.716) 3.87 % (0.262)
Female 16.88 % (0.382) −33.77 % (0.370) −13.76 % (0.662)
Quality of life# −12.98 % (0.648) 16.07 % (0.850) −3.93 % (0.962)
LVEF (per one-unit change) −0.34 % (0.480) 0.05 % (0.975) 0.60 % (0.413)
AVA (per change of 0.1 cm2) −43.45 % (0.295) −86.15 % (0.134) −41.02 % (0.594)
GFR (per one-unit change) −0.54 % (0.271) −2.55 %* (0.050) −0.82 % (0.362)
CAD −2.46 % (0.903) 58.88 % (0.342) −2.38 % (0.949)
Previous PCI −8.61 % (0.596) −1.76 % (0.954) −17.88 % (0.565)
AF 1.18 % (0.943) 87.95 % (0.157) 49.03 % (0.203)
Hypertension −14.53 % (0.121) 26.49 % (0.370) 10.45 % (0.894)
DM −1.62 % (0.935) −20.63 % (0.549) −49.49 %* (0.015)
COPD 25.86 % (0.480) −34.82 % (0.178) −18.21 % (0.373)
EuroScore I (per one-unit change) 1.71 % (0.063) 1.93 % (0.638) 3.11 % (0.167)
EuroScore II (per one-unit change) 4.48 % (0.086) 4.92 % (0.605) 5.01 % (0.257)
STS Score (per one-unit change) 9.48 %** (0.007) 24.86 % (0.117) 16.30 % (0.133)
proBNP (per 100 pg/ml change) 0.045 % (0.721) 0.104 % (0.712) 0.011 % (0.958)
p-values in parentheses; *p <0.05, **p <0.01, ***p <0.001
Not tested due to an insufficient number of events: previous MI, previous stroke, previous CABG, liver disease, PV
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commonly used risk scores, we suggest that AVA can
be an additional predictor of clinical and economic
outcomes.
Recently, the national GARY registry has published the
first data for TAVI and AVR across Germany. Broadly
speaking our results are consistent with this data, certainly
in terms of trends between treatments, although the spe-
cific measures that are reported in the paper do differ in
magnitude. Although no data was given on THsP, the au-
thors do comment in their discussion that “The length of
hospitalization was rather similar [between the different
treatment groups], and accordingly no critical factor in
comparing the techniques”, which may be a point of differ-
ence between the two studies [3].
Hospital LoS is a metric that is highly relevant for local
and national level decision makers due to its obvious im-
pact on resources and operating logistics within secondary
healthcare settings. Not only absolute values are important,
but also variability and predictability, in order to improve
efficiency. We report highly transparent the length of hos-
pitalisation and show large differences and corresponding
variability, with TF-AVI and AVR patients having the shor-
test LoS. Comparisons with other studies are inherently
challenging due to a lack of uniform definitions, variations
between healthcare systems, and limited data on alternative,
heart-team established strategies. LoS generally ranges be-
tween 5 and 13 days for TAVI, [16–18] and 9 and 20 days
for AVR [19–22]. But as with other studies, the LoS is not
only a consequence of clinical outcomes but also local
management practice and, potentially, funding consid-
erations. Without a common definition of LoS that in-
cludes stays in other facilities immediately after discharge
from the treating centre, it is difficult to compare and in-
terpret the data. We suggest that length of “total hospital-
isation since procedure” (THsP) is comprehensive.
As a result of the described risk-selection, comparisons
between treatment groups or risk prediction may always
be subject to a substantial selection bias. In contrast,
within group risk prediction is more appropriate and, ac-
cording to our univariate and multivariate analyses, TA
procedure and AVA were significant and independent
predictors of THsP irrespective of the common risk scores.
It is well known that TA-TAVI has different outcomes
compared with TF-TAVI, and this is due to multiple factors
predominantly related to underlying differences which drive
the choice of a TA approach rather than the TF route. AVA
presents a new concept, which however is probably best
interpreted as a marker for worsening medical condition.
As the AVA decreases and the stenosis pathology worsens,
the effects on the cardiac and circulatory systems, even at
the sub-clinical level, lead to a poorer prognosis and the
need for more resource utilization for patient recovery. As
mentioned above, AVA is not used in the commen risk
scores, but parameters associated with the development of
degenerative aortic valve stenosis such as chronic kidney
failure or patient age are. Thus, when caluclating the risk
scores, AVA might have an indirect impact on the result of
the risk scores.
Most previous studies focusing on risk prediction for
TAVI and/or AVR focus on postoperative factors, such
as complications, for predicting clinical and economic
outcomes [15, 18, 22–29]. In one of the few exceptions,
Green et al. analyzed the association between preopera-
tive frailty status and LoS in elderly patients (mean age
86 years), and showed that a high frailty score was asso-
ciated with a longer LoS [29]. We examined the impact
of self-reported quality of life as this is the only part of
this frailty score included in our study, but it didn’t show
any impact on LoS.
There are multiple benefits to being able to preopera-
tively predict resource usage for patients. From a hos-
pital perspective it allows the best placement of efforts
and optimal planning to achieve the greatest throughput
of patients whilst achieving the best clinical outcomes.
This is obviously an asset for the hospital as it maxi-
mises productivity and limits losses. Efficient planning
should enable more procedures whilst maintaining con-
sistent staff levels and should result in fewer cancelled
elective procedures as a consequence of unavailability of
beds. This also has a direct benefit for the patient, who
is more likely to receive optimal planned care and to ex-
perience minimal delays in procedures, transfers to other
facilities, etc. All of these may be compromised by unex-
pected resource utilization leading to substandard care
resulting from pressures on the system. Finally, the drive
towards reducing THsP is also due to the benefit of re-
ducing non-procedural secondary complications such as
hospital acquired infections.
Study limitations
Strikingly, within the boundaries of the study design and
inclusion/exclusion criteria, there appears to be a num-
ber of important differences in patients from either the
TAVI and the AVR group. Therefore, it would be highly
biased and consequently misleading to make direct com-
parisons of the results between the groups. As shown in
Table 2, outliers strongly affect the force of expression,
particularly in small numbers of cases. In contrast to
purely medical approaches, however, outliers are of par-
ticular interest in health economic considerations. From
a societal perspective, outliers influence the overall costs
of the treatment. In addition, outliers also affect the gap
between actual costs and reimbursement from a hospital
perspective and are therefore critical for a number of
economic considerations from different perspectives.
Moreover, our initial study design included the enroll-
ment of drug patients, analagous to the conservative treat-
ment arm from PARTNER B, but it was soon evident that
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these patients were rarely considered inoperable and were
typically offered TAVI. This directly reflects the current
clinical practice in our, and presumably other centers, and
demonstrates the very limited number of patients presen-
ting with a “true” contraindication for TAVI or AVR. It
however remains unclear whether these “borderline” pa-
tients are a consequence of a shift in perceptions about eli-
gibility for TAVI or surgery, and if so what impact their
inclusion will have on mortality and mobidity affect-
ing comparisons between with pivotal studies such as
PARTNER.
Conclusion
We present here results from the prospective TAVI Cal-
culation of Costs Trial (TCCT) aimed at evaluating the
in-hospital resource use in the treatment of severe aortic
valve stenosis in elderly patients. Our findings reveal
fundamental differences between patient groups, and dif-
ferent requirements and use of resources. We show that,
in addition to the commonly used risk scores, in TAVI
patients the preoperative aortic valve area is an inde-
pendent and so far unknown predictor of hospital length
of stay.
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